Unión Europea - alemán - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - fettleibigkeit - anti-fett-präparate, exkl. diät-produkte - als ergänzung zu diät und bewegung zur behandlung von adipösen patienten (bmi 30 kg/m2) oder von übergewichtigen patienten (bmi 27 kg/m2) mit begleitenden risikofaktor(en), wie typ-2-diabetes oder dyslipidämie (siehe abschnitt 5.

Unión Europea - alemán - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - mittel gegen dermatitis, ausgenommen corticosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - tiapridhydrochlorid - tropfen zum einnehmen, lösung - tiapridhydrochlorid (12851) 15,321 gramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - milrinon - injektionslösung - teil 1 - injektionslösung; milrinon (22796) 20 milligramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - adenosin - injektionslösung - teil 1 - injektionslösung; adenosin (03304) 6 milligramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-synthelabo gmbh (3073784) - amisulprid - filmtablette - teil 1 - filmtablette; amisulprid (23671) 400 milligramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-synthelabo gmbh (3073784) - amisulprid - tablette - teil 1 - tablette; amisulprid (23671) 200 milligramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-synthelabo gmbh (3073784) - amisulprid - tablette - teil 1 - tablette; amisulprid (23671) 100 milligramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - amiodaronhydrochlorid - injektionslösung - teil 1 - injektionslösung; amiodaronhydrochlorid (21609) 150 milligramm

Alemania - alemán - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sanofi-aventis deutschland gmbh (8030868) - amiodaronhydrochlorid - tablette - teil 1 - tablette; amiodaronhydrochlorid (21609) 200 milligramm